Dapagliflozin

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses dapagliflozin propanediol monohydrate 10 mg oral tablet. Indication: To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease.